Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 10/20 | 1.00 |
| ▸ | KDM4C | Q9H3R0 | 7/20 | 0.74 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.74 |
| ▸ | RAF1 | P04049 | 2/20 | 0.70 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.70 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | THRB | P10828 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15032643 | 0.91 | TDP2 (0.84) | TDP2KDM4CSIRT1RAF1MAP2K1 | |
| SCHEMBL20442139 | 0.85 | TDP2 (0.74) | TDP2KDM4CRAF1MAP2K1KDM4E | |
| SCHEMBL2179691 | 0.85 | KDM4C (1.00) | TDP2KDM4CSIRT1RAF1MAP2K1 | |
| SCHEMBL2181779 | 0.85 | TDP2 (1.00) | TDP2KDM4CSIRT1RAF1MAP2K1 | |
| SCHEMBL3472993 | 0.84 | KDM4C (1.00) | TDP2KDM4CSIRT1RAF1MAP2K1 | |
| SCHEMBL2180580 | 0.83 | TDP2 (1.00) | TDP2KDM4CSIRT1RAF1MAP2K1 | |
| SCHEMBL2183740 | 0.82 | TDP2 (1.00) | TDP2KDM4CSIRT1RAF1MAP2K1 | |
| SCHEMBL2186422 | 0.81 | KDM4C (1.00) | TDP2KDM4CSIRT1RAF1MAP2K1 | |
| SCHEMBL2183454 | 0.81 | TDP2 (0.76) | TDP2KDM4CSIRT1RAF1MAP2K1 | |
| SCHEMBL15032641 | 0.81 | TDP2 (0.76) | TDP2KDM4CSIRT1RAF1MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115427032-B | Pharmaceutical combination and use thereof | 浙江养生堂天然药物研究所有限公司 | 2026-05-15 | — | — | CN | claimed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| WO-2025027090-A1 | INHIBITORS OF CELL ENVELOPE PROTEINASES FROM LACTIC ACID BACTERIA | DANMARKS TEKNISKE UNIVERSITET (DK) | 2025-02-06 | — | — | WO | claimed |
| CN-117017995-A | Application of isolated enzyme inhibitor in anti-tumor aspect | 福州大学 | 2023-11-10 | — | — | CN | claimed |
| EP-4129282-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-02-08 | — | — | EP | claimed |
| EP-4119145-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2023-01-18 | — | — | EP | claimed |
| CN-115427032-A | Pharmaceutical composition and use thereof | 浙江养生堂天然药物研究所有限公司 | 2022-12-02 | — | — | CN | claimed |
| WO-2010072807-A2 | INHIBITORS OF CYSTATHIONINE BETA SYNTHASE TO REDUCE THE NEUROTOXIC OVERPRODUCTION OF ENDOGENOUS HYDROGEN SULFIDE | FONDATION JEROME LEJEUNE (FR) | 2010-07-01 | — | — | WO | claimed |
| CN-115427032-B | Pharmaceutical combination and use thereof | 浙江养生堂天然药物研究所有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-117017995-B | Application of isolated enzyme inhibitor in anti-tumor aspect | 福州大学 | 2025-11-07 | — | — | CN | disclosed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2025027090-A1 | INHIBITORS OF CELL ENVELOPE PROTEINASES FROM LACTIC ACID BACTERIA | DANMARKS TEKNISKE UNIVERSITET (DK) | 2025-02-06 | — | — | WO | disclosed |
| CN-115361945-B | Pharmaceutical combination and use thereof | 浙江养生堂天然药物研究所有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-117017995-A | Application of isolated enzyme inhibitor in anti-tumor aspect | 福州大学 | 2023-11-10 | — | — | CN | disclosed |
| WO-2018140762-A1 | INHIBITORS OF HIV-1 INTEGRASE MULTIMERIZATION | INSTITUTE FOR CANCER RESEARCH d.b.a THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2018-08-02 | — | — | WO | disclosed |
| US-9073941-B2 | Compounds and methods for treating tuberculosis infection | ACADEMIA SINICA (TW) | 2015-07-07 | — | — | US | disclosed |
| US-9073941-B2 | Compounds and methods for treating tuberculosis infection | ACADEMIA SINICA (TW) | 2015-07-07 | — | — | US | disclosed |
| US-20130158037-A1 | COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION | ACADEMIA SINICA (TW) | 2013-06-20 | — | — | US | disclosed |
| US-20130158037-A1 | COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION | ACADEMIA SINICA (TW) | 2013-06-20 | — | — | US | disclosed |
| WO-2010072807-A2 | INHIBITORS OF CYSTATHIONINE BETA SYNTHASE TO REDUCE THE NEUROTOXIC OVERPRODUCTION OF ENDOGENOUS HYDROGEN SULFIDE | FONDATION JEROME LEJEUNE (FR) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158037-A1 | COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION | TALDO1, PGD, DLD | TDP2 3811/4885KDM4C 1158/4885SIRT1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.